𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of recombinant beta interferon in patients with advanced non-small-cell lung carcinoma

✍ Scribed by Ettinger, David S. ;Harwood, Kerry

Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
238 KB
Volume
16
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Eighteen patients with advanced non-smallcell lung cancer (NSCLC) received recombinant beta interferon, 90 million units three times weekly. No complete or partial responses were seen. Five patients had stable disease for several months. Most patients experienced some toxicity, most commonly fever and chills. No dose reduction of interferon had to be made due to toxicity. Tachyphylaxis to symptoms of fever and chills occurred in 1 most patients. While 33% of patients developed beta-interferon-binding antibodies, the incidence of interferon-neutralizing activity was 0%. This dose and schedule of beta interferon did not result in significant anti-tumor effects in advanced NSCLC. Stabilization of disease for up to 9 rnonths in patients with previously progressive disease was of interest. Tachyphylaxis of symptoms should allow for dose escalation within patients. A doseescalating study has been initiated to evaluate the efficacy of beta interferon when given at each patient's maximally tolerated dose.

πŸ“œ SIMILAR VOLUMES

A Phase II study of irinotecan in patien
A Phase II study of irinotecan in patients with advanced renal cell carcinoma
✍ Karim Fizazi; FrΓ©dΓ©ric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 3 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p

Prolonged gemcitabine infusion in advanc
Prolonged gemcitabine infusion in advanced non–small cell lung carcinoma : A randomized Phase II study of two different schedules in combination with cisplatin
✍ Anna Ceribelli; Cesare Gridelli; Filippo De Marinis; Alessandra Fabi; Teresa Gam πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 86 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Preclinical and clinical evidence suggests that a fixed infusion rate of 10 mg/m^2^ per minute may be more effective than the standard 30‐minute infusion of gemcitabine. To investigate the activity and toxicity of the cisplatin plus gemcitabine combination with gemcitabin

A phase II study of weekly docetaxel plu
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma
✍ Ji-Youn Han; Dae Ho Lee; Hae Young Kim; Eun Kyung Hong; Sung Min Yoon; Jong Ho C πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 86 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Docetaxel is an active agent in advanced nonsmall‐cell lung carcinoma (NSCLC) and demonstrates preclinical and clinical synergism with capecitabine. We conducted the current Phase II study to evaluate the efficacy and safety of the docetaxel/capecitabine combination in ch